Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Giorgio, Lambru"'
Autor:
Piero Barbanti, Peter J. Goadsby, Giorgio Lambru, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background The multinational phase 3b DELIVER trial was designed to evaluate the efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures across 17 countries. In the placebo-controlled p
Externí odkaz:
https://doaj.org/article/7a81ae83aa2c4873bde25a68ab3a5515
Autor:
Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner, Giorgio Lambru
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-9 (2022)
Abstract Background Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness of CGRP MABs in resis
Externí odkaz:
https://doaj.org/article/0585fd94935644d48509129b2bd79bd4
Autor:
Raffaele Ornello, Carlo Baraldi, Simona Guerzoni, Giorgio Lambru, Anna P. Andreou, Bianca Raffaelli, Astrid Gendolla, Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Sabina Cevoli, Valentina Favoni, Fabrizio Vernieri, Claudia Altamura, Antonio Russo, Marcello Silvestro, Elisabetta Dalla Valle, Andrea Mancioli, Angelo Ranieri, Gennaro Alfieri, Nina Latysheva, Elena Filatova, Jamie Talbot, Shuli Cheng, Dagny Holle, Armin Scheffler, Tomáš Nežádal, Dana Čtrnáctá, Jitka Šípková, Zuzana Matoušová, Alfonsina Casalena, Maurizio Maddestra, Stefano Viola, Giannapia Affaitati, Maria Adele Giamberardino, Francesca Pistoia, Uwe Reuter, Simona Sacco
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available data
Externí odkaz:
https://doaj.org/article/62e111c3fc11417ba73c91df8a1fe766
Publikováno v:
Cephalalgia Reports, Vol 5 (2022)
Background: Temporomandibular disorders (TMD) and headaches are prevalent among the global population. Patients often suffer from both conditions, and they are likely to be associated in a bidirectional way. However, the nature of the association rem
Externí odkaz:
https://doaj.org/article/50e7e279da284351bef9b3d68a764155
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background Clinical trials have shown the safety and clinical superiority of erenumab compared to placebo in chronic migraine (CM). The aim of this analysis is to evaluate the effectiveness and tolerability of erenumab in a real-world settin
Externí odkaz:
https://doaj.org/article/c5d43970fa5e4e6f9ac2fde43a6bf849
Autor:
Raffaele Ornello, Carlo Baraldi, Simona Guerzoni, Giorgio Lambru, Matteo Fuccaro, Bianca Raffaelli, Astrid Gendolla, Piero Barbanti, Cinzia Aurilia, Sabina Cevoli, Valentina Favoni, Fabrizio Vernieri, Claudia Altamura, Antonio Russo, Marcello Silvestro, Elisabetta Dalla Valle, Andrea Mancioli, Angelo Ranieri, Gennaro Alfieri, Nina Latysheva, Elena Filatova, Jamie Talbot, Shuli Cheng, Dagny Holle, Armin Scheffler, Tomáš Nežádal, Dana Čtrnáctá, Jitka Šípková, Zuzana Matoušová, Lucia Sette, Alfonsina Casalena, Maurizio Maddestra, Stefano Viola, Giannapia Affaitati, Maria Adele Giamberardino, Francesca Pistoia, Uwe Reuter, Simona Sacco
Publikováno v:
Frontiers in Neurology, Vol 12 (2021)
Objective: We reported gender-specific data on the efficacy and safety of erenumab, a monoclonal antibody antagonizing the calcitonin gene-related peptide (CGRP) receptor.Methods: Our pooled patient-level analysis of real-world data included patients
Externí odkaz:
https://doaj.org/article/15f9c2554d6c4e1285b954009539d925
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 13 (2020)
Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of
Externí odkaz:
https://doaj.org/article/cb2c3302f4a94a33bae4bcb78f2f440d
Autor:
Adnan Al-Kaisy, Stefano Palmisani, Angela Santos, Anand Rotte, Giorgio Lambru, Samuel Wesley, David Pang, Roy Carganillo
Publikováno v:
Neuromodulation: Technology at the Neural Interface. 25:103-113
BACKGROUND Refractory chronic migraine (rCM) is a highly disabling condition for which novel safe and effective treatments are needed. Safety and long-term efficacy of paresthesia-free high cervical 10 kHz spinal cord stimulation (SCS) were here pros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6610564bdd05797552ccd4ef0163c04
https://doi.org/10.1111/ner.13465
https://doi.org/10.1111/ner.13465
Publikováno v:
The Journal of Headache and Pain, Vol 18, Iss 1, Pp 1-3 (2017)
Externí odkaz:
https://doaj.org/article/89ec0c482a7e4d54970121b230d73a01
Autor:
Carl Bradley, Nicholas Silver, Paul Edey, Rebecca Stuckey, Peter J. Goadsby, Iain Strickland, Angela Abdallah, Madeleine Murphy, Stuart Weatherby, Giorgio Lambru, Fayyaz Ahmed, Fiona Greenwood, Eric Liebler
Publikováno v:
British Journal of Healthcare Management. 27:1-11
Background/Aims Beginning in April 2019, non-invasive vagus nerve stimulation was included in the NHS Innovation and Technology Payment programme. The programme guaranteed reimbursement of at least a 3-month course of treatment using gammaCore, throu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::036c6f6cc3f7061423011837ad095a8c
https://doi.org/10.12968/bjhc.2021.0126
https://doi.org/10.12968/bjhc.2021.0126